1. Home
  2. PODD vs EBR Comparison

PODD vs EBR Comparison

Compare PODD & EBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • EBR
  • Stock Information
  • Founded
  • PODD 2000
  • EBR 1962
  • Country
  • PODD United States
  • EBR Brazil
  • Employees
  • PODD N/A
  • EBR N/A
  • Industry
  • PODD Medical/Dental Instruments
  • EBR Electric Utilities: Central
  • Sector
  • PODD Health Care
  • EBR Utilities
  • Exchange
  • PODD Nasdaq
  • EBR Nasdaq
  • Market Cap
  • PODD 18.2B
  • EBR 17.3B
  • IPO Year
  • PODD 2007
  • EBR N/A
  • Fundamental
  • Price
  • PODD $325.03
  • EBR $7.32
  • Analyst Decision
  • PODD Buy
  • EBR
  • Analyst Count
  • PODD 18
  • EBR 0
  • Target Price
  • PODD $317.61
  • EBR N/A
  • AVG Volume (30 Days)
  • PODD 986.1K
  • EBR 1.2M
  • Earning Date
  • PODD 05-08-2025
  • EBR 06-06-2025
  • Dividend Yield
  • PODD N/A
  • EBR 3.82%
  • EPS Growth
  • PODD 67.46
  • EBR 124.86
  • EPS
  • PODD 5.55
  • EBR 0.75
  • Revenue
  • PODD $2,198,900,000.00
  • EBR $7,303,995,794.00
  • Revenue This Year
  • PODD $23.72
  • EBR $4.95
  • Revenue Next Year
  • PODD $17.56
  • EBR $10.06
  • P/E Ratio
  • PODD $58.58
  • EBR $9.90
  • Revenue Growth
  • PODD 23.48
  • EBR 14.21
  • 52 Week Low
  • PODD $172.07
  • EBR $5.45
  • 52 Week High
  • PODD $329.33
  • EBR $7.83
  • Technical
  • Relative Strength Index (RSI)
  • PODD 70.12
  • EBR 46.56
  • Support Level
  • PODD $315.91
  • EBR $7.28
  • Resistance Level
  • PODD $329.10
  • EBR $7.45
  • Average True Range (ATR)
  • PODD 6.82
  • EBR 0.15
  • MACD
  • PODD -0.15
  • EBR -0.03
  • Stochastic Oscillator
  • PODD 81.61
  • EBR 29.23

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

About EBR Centrais Electricas Brasileiras S A (Each representing one Common Share)

Centrais Eletricas Brasileiras SA is engaged in the generation, transmission, and commercialization of electricity in Brazil. The company operates a portfolio of wind, thermal, hydro, and nuclear power plants located throughout the country. Its segments are Generation which consists of the generation of electric energy and the sale of energy to distribution companies and free consumers, and commercialization; Transmission which consists of the transmission of electric energy; and Administration activities mainly represent the Company's cash management, the management of the compulsory loan, and the management of business in SPEs, and others.

Share on Social Networks: